Cargando…
不同机制所致的血管紊乱化生长的共同干预——安罗替尼治疗右肺鳞癌合并血栓闭塞性脉管炎1例
BACKGROUND AND OBJECTIVE: To date, there is no effective treatment for thromboangiitis obliterans (TAO). Anlotinib, as a third-line therapy, is recommended for patients with refractory advanced non-small cell lung cancer (NSCLC). We presented a case report of a patient suffering from right lung squa...
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
中国肺癌杂志编辑部
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7007391/ https://www.ncbi.nlm.nih.gov/pubmed/31948540 http://dx.doi.org/10.3779/j.issn.1009-3419.2020.01.10 |